北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300016 北陆药业

已收盘 05-15 15:00:00

{"stockData":{"symbol":"300016","market":"SZ","secType":"STK","nameCN":"北陆药业","latestPrice":5.03,"timestamp":1715756580000,"preClose":5.11,"halted":0,"volume":7727550,"delay":0,"floatShares":491000000,"shares":492000000,"eps":-0.1481,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.08,"latestTime":"05-15 15:00:00","open":5.12,"high":5.12,"low":5,"amount":39093000,"amplitude":0.0235,"askPrice":5.04,"askSize":580,"bidPrice":5.03,"bidSize":504,"shortable":0,"etf":0,"ttmEps":-0.1481,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715823000000},"adr":0,"adjPreClose":5.11,"symbolType":"stock","openAndCloseTimeList":[[1715736600000,1715743800000],[1715749200000,1715756400000]],"highLimit":5.62,"lowLimit":4.6,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":491935061,"pbRate":1.62,"roa":"--","roe":"0.7%","epsLYR":-0.15,"committee":0.068502,"marketValue":2474000000,"floatMarketCap":2471000000,"peRate":-33.963537,"changeRate":-0.0157,"turnoverRate":0.0157,"status":1},"requestUrl":"/m/hq/s/300016","defaultTab":"news","newsList":[{"id":"2435680218","title":"北陆药业：公司一季度毛利率增长主要系产品销售结构的变化导致","url":"https://stock-news.laohu8.com/highlight/detail?id=2435680218","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435680218?lang=zh_cn&edition=full","pubTime":"2024-05-15 18:03","pubTimestamp":1715767385,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业05月15日在投资者关系平台上答复投资者关心的问题。公司年报数据积极向好，看到在研项目中有多个维生素项目～。随着项目的研发及申报进度，我们将逐步披露维生素项目的相关信息，敬请关注。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500030924.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434367658","title":"北陆药业：公司产品未涉及生物合成技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2434367658","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434367658?lang=zh_cn&edition=full","pubTime":"2024-05-10 18:03","pubTimestamp":1715335439,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业05月10日在投资者关系平台上答复投资者关心的问题。参股公司世和基因、芝友医疗及医未医疗主营业务分别涉及高通量基因测序、药物基因组及肿瘤靶向用药的分子诊断试剂、脑科学及AI辅助诊断等，其他业务情况请参见各公司官网及微信公众号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000035939.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434851064","title":"北陆药业(300016.SZ)收到盐酸帕罗西汀肠溶缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2434851064","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434851064?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:57","pubTimestamp":1715248620,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸帕罗西汀肠溶缓释片《药品注册证书》。公告显示，“盐酸帕罗西汀肠溶缓释片”用于治疗成人抑郁症，国家医保目录乙类，由葛兰素史克研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119348.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430261171","title":"【机构调研记录】民生加银基金调研电连技术、北陆药业等7只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2430261171","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430261171?lang=zh_cn&edition=full","pubTime":"2024-04-26 08:02","pubTimestamp":1714089778,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月25日披露的机构调研信息，民生加银基金近期对7家上市公司进行了调研，相关名单如下：1）电连技术 个股亮点：公司对英伟达有公司相关产品的研发送样；公司表示小米公司是公司的重要客户。民生加银基金成立于2008年，截至目前，资产管理规模1474.6亿元，排名40/203；资产管理规模1226.63亿元，排名36/203；管理公募基金数157只，排名40/203；旗下公募基金经理29人，排名42/203。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600016038.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430478689","title":"北陆药业：华安证券、山西证券等多家机构于4月24日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2430478689","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430478689?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:34","pubTimestamp":1714034065,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月25日北陆药业发布公告称华安证券谭国超 谢涛 刘洪飞、山西证券王腾蛟、韫然资管徐康、东财基金王陈怡、广发基金吴晓钢、创钰资管唐小皓、宁波知远资管刘永刚、德瑞恒泰基金赵一帆、民生加银基金李由、华宝基金杜舟 张金涛、天治基金王娟、安联投资张祝源、太平基金闫庚威、东方红徐宏于2024年4月24日调研我司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033301.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429433765","title":"北陆药业：兴全基金、永赢基金等多家机构于4月23日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429433765","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429433765?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:15","pubTimestamp":1713953713,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月24日北陆药业发布公告称兴全基金朱喆丰 厉之千 丁小晨、永赢基金陆凯琳于2024年4月23日调研我司。北陆药业2024年一季报显示，公司主营收入2.08亿元，同比上升10.35%；归母净利润1152.62万元，同比下降8.35%；扣非净利润1144.64万元，同比上升32.95%；负债率37.3%，投资收益84.98万元，财务费用1271.93万元，毛利率55.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400038237.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429510912","title":"北陆药业新提交“北陆药业”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2429510912","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429510912?lang=zh_cn&edition=full","pubTime":"2024-04-24 13:36","pubTimestamp":1713936969,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日北京北陆药业股份有限公司新提交“北陆药业”商标注册申请。商标申请详情如下：今年以来北京北陆药业股份有限公司新申请注册商标2件，截止目前公司共持有注册商标110件，另有25件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400024544.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429691841","title":"北陆药业：博衍基金、融通基金等多家机构于4月22日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429691841","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429691841?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:34","pubTimestamp":1713864851,"startTime":"0","endTime":"0","summary":"受公司持有的以公允价值计量的金融工具在报告期末公允价值波动的影响，报告期内归属于上市公司股东的净利润同比下降 8.35%。报告期内，北陆药业及海昌药业海外市场收入总计达到 1.15亿元，同比增长 132.98%。2023 年度，公司研发投入 12,232.89 万元，同比增长 22.62%。北陆药业2024年一季报显示，公司主营收入2.08亿元，同比上升10.35%；归母净利润1152.62万元，同比下降8.35%；扣非净利润1144.64万元，同比上升32.95%；负债率37.3%，投资收益84.98万元，财务费用1271.93万元，毛利率55.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300034864.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429902779","title":"北陆药业（300016）2024年一季报简析：增收不增利，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2429902779","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429902779?lang=zh_cn&edition=full","pubTime":"2024-04-23 06:03","pubTimestamp":1713823400,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期北陆药业发布2024年一季报。根据财报显示，本报告期中北陆药业增收不增利，盈利能力上升。截至本报告期末，公司营业总收入2.08亿元，同比上升10.35%，归母净利润1152.62万元，同比下降8.35%。本次财报公布的各项数据指标表现一般。公司报告期内合同负债规模环比增幅达36.8%，未完成订单增加，可能的原因有公司交货变慢或者下游需求增强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300009768.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429842910","title":"北陆药业：本次天原药业收购完成后，公司“化药+中药”双轮驱动的战略正式落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2429842910","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429842910?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:04","pubTimestamp":1713776667,"startTime":"0","endTime":"0","summary":"本次天原药业收购完成后，公司“化药+中药”双轮驱动的战略正式落地。九味镇心颗粒是国内首个获批治疗广泛性焦虑症的纯中药制剂。为提升患者的用药体验，提高患者顺应性，公司正在开发添加矫味剂的新处方，新口味九味镇心颗粒完成相应药监部门的批准后将上市销售，更好地满足广大患者的用药需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200019054.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429982964","title":"北陆药业(300016.SZ)发布2023年度业绩，由盈转亏至7175.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429982964","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429982964?lang=zh_cn&edition=full","pubTime":"2024-04-21 17:53","pubTimestamp":1713693180,"startTime":"0","endTime":"0","summary":"北陆药业发布2023年年度报告，该公司营业收入为8.91亿元，同比增长16.30%。归属于上市公司股东的净亏损为7175.71万元。归属于上市公司股东的扣除非经常性损益的净亏损为6954.62万元，同比扩大161.94%。基本每股亏损为0.15元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-21/doc-inasqxpv4229664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-21/doc-inasqxpv4229664.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427059855","title":"北陆药业(300016.SZ)拟斥2.02亿元收购天原药业80%股权 进一步落实中成药领域战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2427059855","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2427059855?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:51","pubTimestamp":1713225060,"startTime":"0","endTime":"0","summary":"北陆药业公告，公司拟以自有资金人民币2.02亿元收购金安国纪集团股份有限公司所持承德天原药业有限公司80%股权，并与天原药业相关股东签署《关于承德天原药业有限公司的股权转让协议》。本次收购完成后，天原药业将成为公司的控股子公司，纳入公司合并报表范围。通过本次股权收购，公司将获得目标公司在中成药领域拥有的多款优势产品，对现有的产品管线形成有力补充，共同打造一个更丰富的产品矩阵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-16/doc-inarynme1895043.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-16/doc-inarynme1895043.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2415110335","title":"北陆药业(300016.SZ)拟收购中成药生产企业天原药业80%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2415110335","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2415110335?lang=zh_cn&edition=full","pubTime":"2024-02-29 18:38","pubTimestamp":1709203080,"startTime":"0","endTime":"0","summary":"北陆药业公告，公司与金安国纪、承德天原药业有限公司、周印军及天原企业管理咨询服务围场满族蒙古族自治县合伙企业签订了《关于承德天原药业有限公司的股权转让意向书》，拟使用自有资金收购金安国纪所持承德天原药业有限公司80%的股权。中成药是公司近几年重点布局的领域，公司拟通过本次股权收购，获得目标公司在中成药领域拥有的多款优势产品，对公司现有的产品管线形成有力补充，共同打造一个更丰富的产品矩阵。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-29/doc-inakszmn9457202.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-29/doc-inakszmn9457202.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2391532085","title":"北陆药业(300016.SZ)竞得亳州市一国有土地使用权 建设第四生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2391532085","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2391532085?lang=zh_cn&edition=full","pubTime":"2023-12-13 15:47","pubTimestamp":1702453620,"startTime":"0","endTime":"0","summary":"北陆药业公告，公司全资子公司陆芝葆药业有限公司近日竞得位于安徽省亳州市编号为2023-40号的国有建设用地使用权，并与亳州市自然资源和规划局签订《国有建设用地使用权出让合同》,出让价款为1611.00万元。安徽省亳州市具有完善的中药产业链及良好的营商环境和成本优势。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-13/doc-imzxwhkx2254315.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-13/doc-imzxwhkx2254315.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"北京市密云区水源西路3号","stockEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":0.045},{"period":"3month","weight":0.2373},{"period":"6month","weight":-0.3406},{"period":"1year","weight":-0.2007},{"period":"ytd","weight":-0.2823}],"companyName":"北京北陆药业股份有限公司","boardCode":"AI0027","perCapita":"16315股","boardName":"医药制造业","registeredCapital":"49193万元","compareEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":0.0418},{"period":"3month","weight":0.0977},{"period":"6month","weight":0.0311},{"period":"1year","weight":-0.0498},{"period":"ytd","weight":0.0574}],"survey":"　　北京北陆药业股份有限公司的主营业务为对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品为钆喷酸葡胺注射液、钆布醇注射液、钆贝葡胺注射液、碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、格列美脲片、瑞格列奈片、九味镇心颗粒、钆喷酸葡胺及辅料、钆布醇及辅料、碘海醇、碘佛醇、碘克沙醇、碘普罗胺及碘帕醇。公司是我国对比剂行业的市场领先者。","serverTime":1715769452297,"listedPrice":17.86,"stockholders":"30105人(较上一季度增加0.95%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北陆药业,300016,北陆药业股票,北陆药业股票老虎,北陆药业股票老虎国际,北陆药业行情,北陆药业股票行情,北陆药业股价,北陆药业股市,北陆药业股票价格,北陆药业股票交易,北陆药业股票购买,北陆药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}